gtglabs.com (GENE) - Company Total Sales Volume

Genetic Technologies relies on a sovereign development cycle, rendering it a resilient defensive asset regardless of the global economy. Patent protection and stringent medical regulations create significant barriers to entry for new players. Diagnostic efficiency is supported by optimized express logistics for biological samples. The company's aggregated sales demonstrate revenue dynamics where 0.01 represents the latest level value.

GENE Genetic Technologies Limited: Company Revenue in the range 07/04/2022 - 10/26/2024

Analytical breakdowns for Genetic Technologies Ltd (GENE)

- market value and analyst target forecast:

Market Chart GTG Labs|GENE - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Genetic Technologies Limited|GENE - Enterprise Value

- shareholders' equity book value data:

Net Asset Value per Share Genetic Technologies|GENE - Company Book Value|Capitalization to Book Value Ratio gtglabs.com|GENE - Company Total Assets

- debt and solvency information:

- business earnings and investment ratios data:

GENE - Net Income|Future Net Profit Genetic Technologies|GENE - P/E Multiple|Projected Price to Earnings Ratio GTG Labs|GENE - PEG Multiple|Enterprise Value to EBITDA Ratio Genetic Technologies Limited|GENE - Operating profit EBITDA|Earnings per share for the trailing year Genetic Technologies|GENE - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months gtglabs.com|GENE - Earnings per share growth in current year|Expected net earnings per share growth next year Genetic Technologies

- sales volume and revenue indicators:

GENE - Company Revenue|Company Projected Revenue GTG Labs|GENE - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Genetic Technologies Limited

Summary company analysis:Genetic Technologies

Original product of Genetic Technologies Limited

The overall sales dynamics of Genetic Technologies (GENE) reflect the efficiency of scaling the business through the licensing of genetic tests to third-party laboratories. This indicator captures actual cash inflows from service sales, allowing for an assessment of real capital inflow and the risk of overpaying for the asset at the cycle peak, which is critical for confirming the issuer's financial stability.

Key competitors